If Biodexa's eRapa treatment is shown to be successful in its Phase 3 study and the treatment gets approved, the company believes it would have first-mover advantage in what it estimates is a $7 ...

We love using the city as our stage, but I like that we always begin with the artist—often, the actual space is the final ...

With invasive carp breeding just across the border, it’s not a question of if, but when they arrive in Canada. Now federal ...